

OTCQB Certification

I, Nicholas Sosiak, Chief Financial Officer of Cannara Biotech Inc. ("the Company"), certify that:

- The Company is registered or required to file periodic reporting with the SEC or is exempt from SEC registration as indicated below:

REGISTERED or REPORTING WITH THE SEC:

- ☐ Company is registered under Section 12(g) of the Exchange Act
☐ Company is reporting under Section 15(d) of the Exchange Act.
☐ Company is a bank that reports to a Bank Regulator under Section 12(i) of the Exchange Act
☐ Company is reporting under Regulation A (Tier 2)
☐ Other (describe) _____

EXEMPT FROM SEC REGISTRATION/NO SEC REPORTING OBLIGATIONS:

- ☒ Company is exempt from registration under Exchange Act Rule 12g3-2(b)
☐ Company is a bank that is non-SEC reporting but is current in its reporting to a Banking Regulator
☐ Company is reporting under the Alternative Reporting Company Disclosure Guidelines and is otherwise exempt from registration and not required to file periodic reporting

- The Company is current in its reporting obligations as of the most recent fiscal year end and any subsequent quarters, and such information has been posted either on the SEC's EDGAR system or the OTC Disclosure & News Service, as applicable.
- The company is duly organized, validly existing and in good standing under the laws of the state or jurisdiction in which the Company is organized or does business.
- The share information below is for the primary OTCQB traded security as of the latest practicable date:

US Trading Symbol:		<u>LOVFF</u>	<u>As of (date):</u>
Shares Authorized	(A)	<u>Unlimited</u>	<u>2023-12-20</u>
Total Shares Outstanding	(B)	<u>90,018,952</u>	<u>2023-12-20</u>
Number of Restricted Shares ¹	(C)	<u>2,219,969</u>	<u>2023-12-20</u>
Unrestricted Shares Held by Officers, Directors, 10% Control Persons & Affiliates	(D)	<u>44,741,386</u>	<u>2023-12-20</u>
Public Float: <i>Subtract Lines C and D from Line B</i>	(E)	<u>45,277,566</u>	<u>2023-12-20</u>
% Public Float: <i>Line E Divided by Line B (as a %)</i> ²	(F)	<u>50.30%</u>	<u>2023-12-20</u>
Number of Beneficial Shareholders of at least 100 shares ³	(G)	<u>4643</u>	<u>2023-12-26</u>

¹ Restricted Shares means securities that are subject to resale restrictions for any reason. Your transfer agent should be able to provide the total number of restricted securities.

² Public Float means the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "10 percent Control Person"), or any Affiliates thereof, or any Family Members of officers, directors, and control persons. Family Member shall mean a Person's spouse, parents, children, and siblings, whether by blood, marriage or adoption, or anyone residing in such Person's home. OTCQB traded securities are required to have a freely traded public float of at least 10% of the shares outstanding unless an exemption applies.

³ Beneficial Shareholder means any person who, directly or indirectly has or shares voting power of such security or investment power, which includes the power to dispose, or to direct the disposition of, such security. OTCQB traded securities are required to have at least 50 beneficial shareholders unless an exemption applies.

5. Convertible Debt:

The following is a complete list of all promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities that were issued or outstanding at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this OTCQB Certification. **(If the note is no longer outstanding as of the current date, but was outstanding during the previously described period, the note must still be disclosed in the table below.):**

☐ Check this box to confirm there were no promissory notes, convertible notes, or other convertible debt arrangements issued or outstanding at any point during this period.

Date of Note Issuance	Principal Amount at Issuance (\$)	Outstanding Balance (\$) (include accrued interest)	Maturity Date	Conversion Terms (e.g., pricing mechanism for determining conversion of instrument to shares)	# Shares Converted to Date	# of Potential Shares to be Issued Upon Conversion ⁴	Name of Noteholder (entities must have individual with voting / investment control disclosed). ⁵	Reason for Issuance (e.g., Loan, Services, etc.)
June 21, 2021	5,700,000	6,217,870 (as at August 31, 2023) 6,279,878 (as at November 30, 2023)	January 31, 2025	Conversion at \$1.80 per share	-	3,166,667 common shares upon conversion	Olymbec Investment Inc., owned at 50% by Derek Stern Family Trust and 50% by Richard Stern Family Trust	Loan for asset acquisition
Total Outstanding Balance:		6,279,878		Total Shares:	-	3,166,667		

Use the space below to provide any additional details, including footnotes to the table above:

N/A

6. Disclosure and Administrative Service Providers:

Annual Report Preparation:

⁴ The total number of shares that can be issued upon full conversion of the Outstanding Balance. The number should not factor any "blockers" or limitations on the percentage of outstanding shares that can be owned by the Noteholder at a particular time. For purposes of this calculation, please use the current market pricing (e.g. most recent closing price, bid, etc.) of the security if conversion is based on a variable market rate.

⁵ International Reporting Companies may elect not to disclose the names of noteholders who are non-affiliates of the company. "Affiliate" is a Person that directly, or indirectly through one or more intermediaries, controls or is controlled by, or is under common control with, an officer, a director, or a shareholder beneficially owning 10 percent or more of the Company's outstanding shares.

List any law firm(s) and attorney(s) (including internal counsel) that acted as the Company's primary legal counsel in preparing its most recent annual report. (If no attorney assisted in putting together the disclosure, identify the person(s) who prepared the disclosure and their relationship to the company.)

Brian Sherman, Cannara Biotech Inc.'s internal general and VP legal affairs
Dentons Canada S.E.N.C.R.L, Charles Spector

Ongoing Disclosure and Administrative Services:

List any other attorney or service provider, if different than the primary legal counsel listed above, that assisted the company during the prior fiscal year on any matter related to preparation of company disclosure documents, corporate actions and activities related to submission of a Form 211 or OTC Markets' Application. **Please include the following items in this list: firm name, firm address, primary contact name and description of services provided.** If none, please state "None."

Not different from primary legal counsel listed above

7. Investor Relations Providers:

The following is a complete list of third-party providers engaged by the Company, its officers, directors or controlling shareholders, at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this OTCQB Certification, to provide investor relations services, public relations services, marketing, brand awareness, stock promotion, or any other related services to the Company. **Please include the following items in this list: firm name, firm address, primary contact name and description of services provided.** If none, please state "None."

Investor relations services:

Glen Akselrod - Bristol Capital Ltd., 250 Rodinea Rd, 2nd Floor, Vaughan, Ontario, L6A 4P5

8. Officers, Directors and 5% Control Persons:

The following is a complete list of Officers, Directors and 5% Control Persons (control persons are beneficial owners of five percent (5%) or more of any class of the issuer's equity securities). Preferred shares, options, warrants that can be converted into common shares within the next 60 days should be included in the shareholdings listed below. **If any of the beneficial shareholders are corporate entities, provide the name and address of the person(s) owning or controlling such corporate entities. If the corporate entity owning 5% or more does not have a person(s) owning or controlling it, provide a note explaining why. For nominee accounts owning 5% or more, provide the name of the 5% beneficial shareholder for this account. If there are no beneficial shareholders of 5% or more behind a nominee account, add a note confirming this.**

Name (First, Last)	Position/company affiliation (ex: CEO, 5% control person)	City and State (And Country if outside US)	Number of Shares Owned (List common, preferred, warrants and options separately)	Class of shares owned	Percentage of Class of Shares Owned (undiluted)
Javaa Private Equity Inc. (controlled by Zohar Krivorot)	Control person (company controlled by CEO)	8000 Decarie Boulevard, suite 460 Montreal, Quebec	24,258,982 common shares	Common shares	26.95%

		H4P 2S4 Canada			
Zohar Krivorot	CEO	21 Croissant Applewood Hampstead, Quebec H3X 3B6 Canada	1,124,808 RSUs	N/A	-
Derek Stern	Board member	21 Lyncroft road Hampstead, Quebec H3X 3E3 Canada	376,040 common shares 64,375 RSUs	Common shares	0.42%
Olymbec Investments Inc. (50% owned by Derek Stern)	Control person (company controlled by a Board member)	333 Decarie Boulevard 5th floor Ville Saint-Laurent, Quebec H4N 3M9 Canada	19,514,757 common shares	Common shares	21.68%
Jack Kay	Board member	23 Bryson Drive Richmond Hill, Ontario L4C 6E2 Canada	219,000 common shares 20,000 stock options 15,000 RSUs	Common shares	0.24%
Mary Durocher	Board member	350 County road 27 South Woodslee, Ontario N0R 1V0 Canada	25,000 stock options 15,000 RSUs	N/A	-
Donald Olds	Board member	4139 Hampton avenue Montreal, Quebec H4A 2L1 Canada	115,562 common shares 50,000 stock options 35,000 RSUs	Common shares	0.13%
Nicholas Sosiak	CFO	986 rue des fuchias Laval, Quebec H7Y 0B4 Canada	209,795 common shares 2,850,000 stock options 250,000 RSUs	Common shares	0.23%
Avi Krivorot	CTO	5897 Beethoven Avenue Côte-St-Luc, Quebec H4W 3B5	47,250 common shares	Common shares	0.05%

		Canada	37,500 common shares		

Use the space below to provide any additional details, including conversion terms of any class of the issuer's equity securities:

N/A

9. Certification:

Date: December 29, 2023

Name of Certifying CEO or CFO: Nicholas Sosiak

Title: Chief Financial Officer

Signature: /s/ Nicholas Sosiak

(Digital Signatures should appear as "/s/ [OFFICER NAME]")